dollars within a span of two months. The Series A1 round was led by YuanSheng Venture Capital, with YuanHe Holdings, Juming Venture Capital, and Linking Capital participating as follow‑on investors.

The funds raised will be used to accelerate the CMC manufacturing and clinical filing of three antibody drugs independently developed on the company’s TavoPrecise platform — namely Tavo111, Tavo103, and Tavo101. The capital will also support expanded R&D efforts for multiple other novel anticancer bispecific antibodies, multispecific antibodies, and Multi‑Cyclic Peptides (MIPs).

Founded in early 2019, Tavotek Biotherapeutics is driven by innovation and committed to continuously improving and enhancing patients’ quality of life. The company operates R&D centers in Suzhou, China, and Pennsylvania, USA. Its core team members come from leading multinational pharmaceutical companies such as Johnson & Johnson, Abbott, GSK, and Eli Lilly. The founding team collectively averages decades of deep experience in drug R&D and has contributed to launching more than ten globally first‑in‑class blockbuster drugs with annual sales exceeding $1 billion.

Beijing Caihe Law Firm conducted Freedom‑to‑Operate (FTO) due diligence for patent infringement risks in this financing round.